CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

CohBar, Inc. and Morphogenesis, Inc., a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.

Tampa’s Morphogenesis Wants To Cure Cancer With an Affordable Shot

A group of scientists in Tampa is working to make treating cancer as easy as getting a shot. While most of today's cancer treatments tend to be toxic and expensive, UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, is working to develop immunotherapies that are safe and affordable.